Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 07, 2019 16:25 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics Announces Proposed Public Offering of Common Stock

NEW YORK, Aug. 07, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a commercial -stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing...
August 06, 2019 07:30 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics Announces that CMS Grants New Technology Add-on Payment (NTAP) to ELZONRIS®

NEW YORK, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
August 02, 2019 07:00 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics Reports Second Quarter 2019 Financial Results

Net revenue for ELZONRIS® was $13.0 million for the second quarterConference call and live webcast scheduled for today at 8:00 AM ET NEW YORK, Aug. 02, 2019 (GLOBE NEWSWIRE) -- Stemline...
July 29, 2019 07:00 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics to Host Conference Call on Second Quarter 2019 Financial Results on August 2, 2019

NEW YORK, July 29, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
July 08, 2019 17:50 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics Highlights Recent Clinical and Regulatory Developments and Details Upcoming Milestones following its Annual Shareholder Meeting

NEW YORK, July 08, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
June 17, 2019 07:30 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics Announces Presentation of ELZONRIS (tagraxofusp) Preclinical Data in Systemic Sclerosis, an Autoimmune Disorder, at EULAR Congress

NEW YORK, June 17, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
June 13, 2019 07:30 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics Announces Three ELZONRIS (tagraxofusp) Clinical Presentations at EHA Congress June 13-15

NEW YORK, June 13, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
June 03, 2019 07:30 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics Announces ASCO Presentation of ELZONRIS Phase 2 Clinical Data in CMML and MF; Provides Next Steps for CMML Program

NEW YORK, June 03, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
May 20, 2019 07:00 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics Announces ELZONRIS Clinical Data Selected for Presentation at Upcoming EHA Annual Congress

NEW YORK, May 20, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology...
May 16, 2019 07:00 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics Announces ELZONRIS Clinical Data Selected for Presentation at the Upcoming ASCO Annual Meeting

NEW YORK, May 16, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology...